A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

NCT05313282 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

140

Enrollment

OTHER

Sponsor class

Conditions

C-staged Hepatocellular Carcinoma in BCLC Classification

Interventions

COMBINATION_PRODUCT: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
COMBINATION_PRODUCT: Apatinib combined with Camrelizumab

Sponsor

Sun Yat-sen University

Collaborators

[object Object]